<DOC>
	<DOCNO>NCT00676871</DOCNO>
	<brief_summary>Phase 1 : - Evaluate safety tolerability MEDI-538 give escalate dos continuous IV infusion 4 week adult patient CLL . - Determine maximum tolerate dose ( MTD ) MEDI-538 administer continuous IV infusion 4 week patient population - Describe pharmacokinetics ( PK ) MEDI-538 - Describe immunogenicity ( IM ) MEDI-538 - Determine overall response , define follow : ( 1 ) conversion PD/SD PR/nPR/CR conversion PR nPR/CR use standard NCI-WG criterion ; ( 2 ) conversion MRD positivity MRD negativity use 4-color flow cytometry ; - Describe antitumor activity ( ie , time response duration response ) MEDI-538 patient population . Phase 2 : - To determine overall response adult patient CLL residual disease follow previous therapy CLL . - Describe safety , PK , IM MEDI-538 - Determine time MRD relapse - Determine antitumor activity ( ie , time response , duration response , time progression [ TTP ] ) MEDI-538 patient population .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Antitumor Activity Continuous Intravenous Infusion MEDI-538 Adults With B-Cell Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Phase 1 : - Evaluate safety tolerability MEDI-538 dose 5 , 10 , 15 , 30 , 45 , 60 mg/m2/24h continuous IV infusion 4 week adult patient CLL measurable disease follow previous therapy CLL . Patients measurable disease include patient demonstrated PD , SD , PR follow previous therapy CLL ; - Determine maximum tolerate dose ( MTD ) MEDI-538 administer continuous IV infusion 4 week patient population ; - Describe pharmacokinetics ( PK ) MEDI-538 - Describe immunogenicity ( IM ) MEDI-538 - Determine overall response , define follow : ( 1 ) conversion PD/SD PR/nPR/CR conversion PR nPR/CR use standard NCI-WG criterion ; ( 2 ) conversion MRD positivity MRD negativity use 4-color flow cytometry ; - Describe antitumor activity ( ie , time response duration response ) MEDI-538 patient population . Phase 2 : - Determine overall response adult patient CLL residual disease follow previous therapy CLL . - Describe safety MEDI-538 - Describe PK MEDI-538 - Describe IM MEDI-538 - Determine time MRD relapse - Determine antitumor activity ( ie , time response , duration response , time progression [ TTP ] ) MEDI-538 patient population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Adult men woman least 18 year age ; Written inform consent Heath Insurance Portability Accountability Act ( HIPAA ) authorization ( applies cover entity USA ) obtain patient prior perform studyrelated procedure , include screen visit ; Previous confirmation Bcell CLL characteristic immunophenotype flow cytometry ; MRD positivity , determine 4color flow cytometry bone marrow peripheral blood patient follow previous therapy CLL ; Measurable and/or residual disease follow previous therapy CLL follow : 1 . Measurable disease , determine NCIWG criterion , follow standard firstline salvage therapy ; include patient PD , SD , PR ( Phase 1 ) ; 2 . Residual disease determine measurable disease ( ie , PD , SD , PR ) MRD positivity , determine 4color flow cytometry bone marrow and/or peripheral blood patient CR nPR ( Phase 2 ) ; Time complete last therapy CLL ≥ 3 month ≤ 1 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; Presence livein companion ( relative friend ) agree NOT leave patient unattended &gt; 8 hour per day ; Patient agree refrain engage hazardous occupation activity require complete mental alertness operate machinery drive motor vehicle ; Females , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner sterile sexual partner ) 21 day prior first dose MEDI538 , must agree continue use precaution 3 month last dose MEDI538 . Cessation birth control point discuss responsible physician . Males , unless surgically sterile , must likewise use effective method birth control ( condom spermicide ) must agree continue use precaution 3 month last dose MEDI538 ; Hemoglobin ≥ 10.0 g/dL platelet &gt; 75.0 x 109/L ; Total bilirubin ≤ 1.5 x ULN ; aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , amylase lipase ≤ 2 x ULN ; Serum creatinine ≤ 2 x ULN creatinine clearance ≥ 50 mL/min ; Absolute neutrophil count ( ANC ) &gt; 1.0 × 109/L ; For patient receive previous treatment alemtuzumab , CD4 count must &gt; 200 cells/μL negative status cytomegalovirus ( CMV ) antigen . Receipt MEDI538 previous clinical study ; History allergy reaction component MEDI538 formulation ; History malignancy CLL within 5 year prior study entry , exception basal cell carcinoma skin carcinoma situ cervix successfully treat curative therapy ; Fludarabinerefractory CLL , define failure achieve PR CR/nPR least one fludarabinecontaining regimen , disease progression fludarabine treatment , disease progression responder within 6 month last dose fludarabine ; Known suspect CNS involvement ; Clinical history significant CNS pathology , eg , uncontrolled headache , multiple occurrence confusion , dementia , multiple previous infarct , major brain surgery ; Active infection know bacteremia . Patients document evidence culture positive sepsis active infection require IV antibiotic therapy must complete full course antibiotic treatment clinical laboratory evidence bacterial infection least 2 week prior start therapy MEDI538 . Vaccination ( either preventive therapeutic infectious disease cancer ) within 2 week prior initiation MEDI538 ; Infection human immunodeficiency virus ( HIV1 HIV2 ) , chronic infection hepatitis B C , acute infection hepatitis A ; History serious , chronic autoimmune disease , eg , rheumatoid arthritis , systemic lupus erythematosus , multiple sclerosis ; Elective surgery plan study period 30 day discontinuation MEDI538 ; Autologous stem cell transplantation within 26 week prior study entry ; Allogenic stem cell transplantation solid organ transplant ; Regular dose systemic corticosteroid 4 week prior initiation MEDI538 anticipate need corticosteroid exceed prednisone 20 mg/day equivalent trial , systemic immunosuppressive therapy within 4 week prior study entry ; Any contraindication chronic anticoagulation lowmolecular weight heparin ( LMWH ) ; Inability safe placement prolong use ( least 4 week ) central venous catheter ; Contraindication protocolspecified concomitant medication ( methylprednisolone , antacid , antihistamine ) study ; Presence know human antimurine antibody hypersensitivity immunoglobulins ; Pregnancy ( female childbearing potential must negative urine pregnancy test day first dose MEDI538 , prior dose ) nursing ; Evidence uncontrolled systemic disease ( CLL ) , include autoimmune hemolytic anemia ; Any find upon physical examination history disease behavior , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Inability meet social environment requirement outpatient therapy ( see Section 3.3.4.2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>